Literature DB >> 17725806

Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.

Tetsuro Baba1, Takeshi Hanagiri, Yoshinobu Ichiki, Koji Kuroda, Yoshiki Shigematsu, Makiko Mizukami, Masakazu Sugaya, Mitsuhiro Takenoyama, Kenji Sugio, Kosei Yasumoto.   

Abstract

Both cytotoxic T lymphocytes (CTL) and natural killer (NK) cells may play major roles in the host defense against cancer. However, their relationship against the same tumor remains to be elucidated. Among 26 human lung cancer cell lines established in our laboratory, 10 (38%) exhibited human leukocyte antigen (HLA)-class I haplotype loss and three (12%) lost HLA-class I expression totally by flow cytometry analysis. The two cell lines (E522L and C831L) that lost their expression of HLA-class I in vitro and in vivo were applied for further evaluations. Genetic abnormalities of beta2-microglobulin gene were observed in both E522L (loss of mRNA) and C831L (point mutation). Transduction of the wild-type beta2-microglobulin gene rendered them positive for HLA-class I expression. The CTL were induced from autologous peripheral blood mononuclear cells or regional lymph node lymphocytes by stimulation with wild-type beta2-microglobulin transduced-E522L or -C831L, and they showed tumor-specific cytotoxicity against wild-type beta2-microglobulin-transductant, but not parental cells. In NK cell cytotoxicity, E522L showed high sensitivity to NK cells; however, C831L showed resistance despite loss of HLA-class I expression. E522L expressed MHC class I chain related molecules A/B, but C831L did not. The transduction of the MHC class I chain related molecule A gene from E522L rendered C831L positive for expression and sensitive to NK cell cytotoxicity. Reconstruction of HLA-class I and MHC class I chain related molecules A expression could abrogate evasion from cellular attack by CTL and NK cells, and it may lead to a breakthrough in the development of cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725806     DOI: 10.1111/j.1349-7006.2007.00586.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  17 in total

Review 1.  T-cell-associated cellular immunotherapy for lung cancer.

Authors:  Ke Li; Qing Zhang; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

Review 2.  Current treatment options of T cell-associated immunotherapy in multiple myeloma.

Authors:  Hailing Liu; Yunbao Pan; Shan Meng; Wanggang Zhang; Fuling Zhou
Journal:  Clin Exp Med       Date:  2017-01-24       Impact factor: 3.984

Review 3.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

4.  Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.

Authors:  Tetsuro Baba; Hironobu Shiota; Koji Kuroda; Yoshiki Shigematsu; Yoshinobu Ichiki; Hidetaka Uramoto; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2012-11-03       Impact factor: 3.402

Review 5.  Why has active immunotherapy not worked in lung cancer?

Authors:  A Thomas; G Giaccone
Journal:  Ann Oncol       Date:  2015-07-30       Impact factor: 32.976

6.  Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients.

Authors:  Kosuke Yamaguchi; Hiroki Chikumi; Asuka Shimizu; Miyako Takata; Naoki Kinoshita; Kiyoshi Hashimoto; Masaki Nakamoto; Shinji Matsunaga; Jun Kurai; Naomi Miyake; Shingo Matsumoto; Masanari Watanabe; Akira Yamasaki; Tadashi Igishi; Naoto Burioka; Eiji Shimizu
Journal:  Cancer Sci       Date:  2012-07-10       Impact factor: 6.716

7.  Immunotherapy for lung cancers.

Authors:  Ming-Yi Ho; Shye-Jye Tang; Kuang-Hui Sun; Winnie Yang
Journal:  J Biomed Biotechnol       Date:  2011-01-24

Review 8.  Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.

Authors:  Martin R Jadus; Josephine Natividad; Anthony Mai; Yi Ouyang; Nils Lambrecht; Sandor Szabo; Lisheng Ge; Neil Hoa; Maria G Dacosta-Iyer
Journal:  Clin Dev Immunol       Date:  2012-07-29

Review 9.  Tumor-induced CD8+ T-cell dysfunction in lung cancer patients.

Authors:  Heriberto Prado-Garcia; Susana Romero-Garcia; Dolores Aguilar-Cazares; Manuel Meneses-Flores; Jose Sullivan Lopez-Gonzalez
Journal:  Clin Dev Immunol       Date:  2012-10-17

10.  Tumor Immune Microenvironment Characterization of Primary Lung Adenocarcinoma and Lymph Node Metastases.

Authors:  Yuan Zhou; Xinying Shi; Huan Chen; Beibei Mao; Xue Song; Lingling Gao; Jiao Zhang; Ying Yang; Henghui Zhang; Guo Wang; Wei Zhuang
Journal:  Biomed Res Int       Date:  2021-07-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.